Metabolomic profiling has identified signatures of insulin resistance in skeletal muscle; however, the direct effect of insulin stimulation on these metabolite signatures in humans remains largely unresolved. To address this, we investigated the effect of insulin stimulation on skeletal muscle metabolites in a well characterized cohort of humans spanning the spectrum of insulin sensitivity. Vastus lateralis muscle samples were obtained from endurance athletes, sedentary lean and obese adults, and individuals with type 2 diabetes (n=16,15,15,12, respectively) under basal conditions and 1-hour into a hyperinsulinemic-euglycemic clamp. Metabolomic analysis was performed using UPLC-MS/MS. Basal concentrations of TCA cycle intermediates, including citrate, alpha-ketoglutarate, succinate, fumarate, malate and oxaloacetate, were positively related to insulin sensitivity (steady-state clamp Rd glucose in mg/kg/min; all P<0.01). Most of these relationships strengthened during insulin stimulation, with the strongest relationships observed for malate (r2 = 0.453, P<0.01) and fumarate (r2 = 0.501, P<0.01) that reflected a blunted increase in TCA intermediates during insulin stimulation with insulin resistance. Insulin stimulation lowered most medium- and long-chain acyl-carnitines compared with basal levels; however, this effect was also attenuated as a function of insulin resistance, signaling impaired metabolic flexibility. Notably, basal levels of several acyl-carnitines, including C12:0, C14:0, C16:0 and C18:1, were increased in endurance athletes compared with other groups (all P<0.05). Several amino acids, including leucine, isoleucine and lysine, were negatively related to insulin sensitivity in the basal and insulin stimulated state (all P<0.01). Together these findings indicate that physiologic insulin stimulation exacerbates metabolic signatures of skeletal muscle insulin resistance in humans.


S.A. Newsom: None. L. Perreault: Advisory Panel; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Novo Nordisk A/S. Advisory Panel; Self; Merck & Co., Inc.. Speaker's Bureau; Self; Merck & Co., Inc., AstraZeneca, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc.. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Sanofi. Speaker's Bureau; Self; Sanofi. A. Kerege: None. K.A. Harrison: None. D.E. Kahn: None. T. Nemkov: None. A. D’Alessandro: None. B. Bergman: Research Support; Self; Eli Lilly and Company. Advisory Panel; Spouse/Partner; Novo Nordisk Inc., Merck & Co., Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at